EA202090688A1 - Бис-амидные соединения, активирующие саркомер, и варианты их применения - Google Patents
Бис-амидные соединения, активирующие саркомер, и варианты их примененияInfo
- Publication number
- EA202090688A1 EA202090688A1 EA202090688A EA202090688A EA202090688A1 EA 202090688 A1 EA202090688 A1 EA 202090688A1 EA 202090688 A EA202090688 A EA 202090688A EA 202090688 A EA202090688 A EA 202090688A EA 202090688 A1 EA202090688 A1 EA 202090688A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sarcomer
- variants
- amide
- activating
- bis
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title 1
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 title 1
- 210000002235 sarcomere Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557846P | 2017-09-13 | 2017-09-13 | |
| PCT/US2018/050793 WO2019055590A1 (en) | 2017-09-13 | 2018-09-13 | SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090688A1 true EA202090688A1 (ru) | 2020-07-06 |
Family
ID=63794635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090688A EA202090688A1 (ru) | 2017-09-13 | 2018-09-13 | Бис-амидные соединения, активирующие саркомер, и варианты их применения |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US10723720B2 (enExample) |
| EP (1) | EP3681882A1 (enExample) |
| JP (1) | JP7308816B2 (enExample) |
| KR (1) | KR20200054237A (enExample) |
| CN (1) | CN111601798B (enExample) |
| AR (1) | AR112804A1 (enExample) |
| AU (1) | AU2018332887B2 (enExample) |
| BR (1) | BR112020004800A2 (enExample) |
| CA (1) | CA3075669A1 (enExample) |
| CL (1) | CL2020000610A1 (enExample) |
| CO (1) | CO2020002745A2 (enExample) |
| CR (1) | CR20200116A (enExample) |
| EA (1) | EA202090688A1 (enExample) |
| IL (1) | IL272573B2 (enExample) |
| JO (1) | JOP20200059A1 (enExample) |
| MA (1) | MA50173A (enExample) |
| MX (2) | MX2020002696A (enExample) |
| PE (1) | PE20200924A1 (enExample) |
| PH (1) | PH12020500446A1 (enExample) |
| SA (1) | SA520411524B1 (enExample) |
| SG (1) | SG11202001377PA (enExample) |
| TW (1) | TWI790281B (enExample) |
| UY (1) | UY37879A (enExample) |
| WO (1) | WO2019055590A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018332887B2 (en) | 2017-09-13 | 2022-12-08 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| KR20210016545A (ko) * | 2018-05-29 | 2021-02-16 | 오메로스 코포레이션 | Masp-2 억제제 및 사용 방법 |
| KR20220002885A (ko) * | 2019-03-12 | 2022-01-07 | 암젠 인크 | 심장 트로포닌 활성제의 다형체 및 공결정 |
| JP2022525102A (ja) * | 2019-03-12 | 2022-05-11 | アムジェン インコーポレイテッド | 心臓トロポニン活性化因子の多形 |
| BR112022000915A2 (pt) * | 2019-07-23 | 2022-05-17 | Bayer Ag | Compostos de heteroaril-triazol como pesticidas |
| JP7721142B2 (ja) | 2019-12-04 | 2025-08-12 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CA3159172A1 (en) | 2019-12-04 | 2021-06-10 | Michael Cicirelli | Masp-2 inhibitors and methods of use |
| WO2021113686A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| CA3182633A1 (en) * | 2020-06-17 | 2021-12-23 | Ashok Arasappan | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
| CA3179181A1 (en) * | 2021-03-15 | 2022-09-22 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2023122325A2 (en) * | 2021-12-23 | 2023-06-29 | Regents Of The University Of Michigan | Meta anilide compounds and methods for use of the same to treat diseases and disorders |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662529B2 (ja) * | 1984-07-13 | 1994-08-17 | 三共株式会社 | アミノ酸誘導体 |
| US5952307A (en) | 1994-01-21 | 1999-09-14 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9708119D0 (en) | 1997-04-22 | 1997-06-11 | Glaxo Group Ltd | Chemical compounds |
| AU1082901A (en) | 1999-10-18 | 2001-04-30 | National Jewish Medical And Research Center | Method for modulation of cell phenotype |
| WO2001054506A1 (en) | 2000-01-28 | 2001-08-02 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US6495337B1 (en) | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
| WO2002046419A2 (en) | 2000-11-07 | 2002-06-13 | Board Of Regents, The University Of Texas System | Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| EP1503986B1 (en) | 2001-12-21 | 2015-09-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| WO2004064730A2 (en) | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7595322B2 (en) | 2003-03-27 | 2009-09-29 | Cytokinetics, Inc. | Heterocyclic sulfonamides as modulators of cardiac sarcomeres |
| WO2004094610A2 (en) | 2003-04-21 | 2004-11-04 | Baylor College Of Medicine | Wnt as a factor for cardiac myogenesis |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| JP2005298628A (ja) | 2004-04-09 | 2005-10-27 | Sumitomo Chemical Co Ltd | オレフィン重合触媒成分及びオレフィン重合体の製造方法 |
| AU2005264988B2 (en) | 2004-06-17 | 2011-09-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| EP1959960B1 (en) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007089805A2 (en) | 2006-01-31 | 2007-08-09 | The General Hospital Corporation | Anti-hypertrophic effects and inotropic effects of picot |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| CN104024249A (zh) | 2011-10-17 | 2014-09-03 | 埃南塔制药公司 | 丙型肝炎病毒抑制剂 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| MX394449B (es) * | 2012-01-12 | 2025-03-11 | Univ Yale | Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3. |
| US9895308B2 (en) | 2013-03-14 | 2018-02-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| SI3247707T1 (sl) | 2015-01-22 | 2023-10-30 | MyoKardia, Inc. | S 4-metilsulfonilom substituirane spojine piperidina sečnine, uporabne za zdravljenje srčnih motenj, kot je dilatacijska kardiomiopatija (dcm) |
| CA2979070A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| JP6858716B2 (ja) | 2015-06-26 | 2021-04-14 | アムジエン・インコーポレーテツド | 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法 |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| SG10202111790YA (en) | 2017-06-30 | 2021-12-30 | Amgen Inc | Synthesis of omecamtiv mecarbil |
| AU2018332887B2 (en) | 2017-09-13 | 2022-12-08 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
| HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| WO2020037164A1 (en) | 2018-08-17 | 2020-02-20 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| JP2022525102A (ja) | 2019-03-12 | 2022-05-11 | アムジェン インコーポレイテッド | 心臓トロポニン活性化因子の多形 |
| KR20220002885A (ko) | 2019-03-12 | 2022-01-07 | 암젠 인크 | 심장 트로포닌 활성제의 다형체 및 공결정 |
-
2018
- 2018-09-13 AU AU2018332887A patent/AU2018332887B2/en active Active
- 2018-09-13 JO JOP/2020/0059A patent/JOP20200059A1/ar unknown
- 2018-09-13 EA EA202090688A patent/EA202090688A1/ru unknown
- 2018-09-13 CN CN201880072907.5A patent/CN111601798B/zh active Active
- 2018-09-13 MX MX2020002696A patent/MX2020002696A/es unknown
- 2018-09-13 PE PE2020000339A patent/PE20200924A1/es unknown
- 2018-09-13 CR CR20200116A patent/CR20200116A/es unknown
- 2018-09-13 UY UY0001037879A patent/UY37879A/es not_active Application Discontinuation
- 2018-09-13 US US16/129,862 patent/US10723720B2/en active Active
- 2018-09-13 BR BR112020004800-3A patent/BR112020004800A2/pt not_active Application Discontinuation
- 2018-09-13 MA MA050173A patent/MA50173A/fr unknown
- 2018-09-13 TW TW107132171A patent/TWI790281B/zh active
- 2018-09-13 KR KR1020207010115A patent/KR20200054237A/ko not_active Abandoned
- 2018-09-13 AR ARP180102603A patent/AR112804A1/es unknown
- 2018-09-13 EP EP18783202.7A patent/EP3681882A1/en not_active Withdrawn
- 2018-09-13 WO PCT/US2018/050793 patent/WO2019055590A1/en not_active Ceased
- 2018-09-13 CA CA3075669A patent/CA3075669A1/en active Pending
- 2018-09-13 IL IL272573A patent/IL272573B2/en unknown
- 2018-09-13 SG SG11202001377PA patent/SG11202001377PA/en unknown
- 2018-09-13 JP JP2020514579A patent/JP7308816B2/ja active Active
-
2020
- 2020-03-05 PH PH12020500446A patent/PH12020500446A1/en unknown
- 2020-03-10 CO CONC2020/0002745A patent/CO2020002745A2/es unknown
- 2020-03-10 CL CL2020000610A patent/CL2020000610A1/es unknown
- 2020-03-10 MX MX2022014864A patent/MX2022014864A/es unknown
- 2020-03-12 SA SA520411524A patent/SA520411524B1/ar unknown
- 2020-03-27 US US16/833,321 patent/US11254658B2/en active Active
- 2020-03-27 US US16/833,336 patent/US10899746B2/en active Active
- 2020-10-12 US US17/068,518 patent/US11299479B1/en active Active
-
2022
- 2022-02-15 US US17/672,594 patent/US11780826B2/en active Active
-
2023
- 2023-08-17 US US18/451,757 patent/US20240158372A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| MX2024009886A (es) | Derivados de quinolina como inhibidores de integrina alfa4beta7. | |
| EA202190686A1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| MY195977A (en) | Heterocyclic Compounds and uses Thereof | |
| EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
| EA202090486A2 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| MX388175B (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| EA202192760A1 (ru) | Трициклические соединения | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| EA202190064A1 (ru) | Цианотриазоловые соединения и варианты их применения | |
| EA202091293A1 (ru) | Производные пиридинона и их применение в качестве селективных ингибиторов alk-2 | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| EA202190458A1 (ru) | Составы, содержащие дендример | |
| EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний | |
| EA202190689A1 (ru) | Производные хинолина в качестве ингибиторов интегрина альфа4бета7 |